The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells

References

• Mugnaini EN, Ghosh N. Lymphoma. Prim Care. 2016;43:661–675.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013;19:410–417.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Valdez BC, Thall PF, et al. Vorinostat combined with high-dose gemcitabine, busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphomas. Biol Blood Marrow Transplant. 2015;21:1914–1920.
   PubMed Web of Science ®Google Scholar
• Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23:3–15.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Andersson BS. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen. 2010;51:659–668.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Nieto Y, Murray D, et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012;40:800–810.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Valdez BC, Thall PF, et al. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016;122:2680–2688.
   PubMed Web of Science ®Google Scholar
• Spanswick VJ, Lowe HL, Newton C, et al. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer. 2012;12:436.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–598.
   PubMed Web of Science ®Google Scholar
• Adhikari S, Choudhury S, Mitra PS, et al. Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem. 2008;8:351–357.
   PubMed Web of Science ®Google Scholar
• David KK, Andrabi SA, Dawson TM, et al. Parthanatos, a messenger of death. Front Biosci (Landmark Ed). 2009;14:1116–1128.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Petermann E, Schultz N, et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009;28:2601–2615.
   PubMed Web of Science ®Google Scholar
• Wei H, Yu X. Functions of PARylation in DNA damage repair pathways. Genomics Proteomics Bioinformatics. 2016;14:131–139.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–5599.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17:1579–1589.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–1392.
   PubMed Web of Science ®Google Scholar
• Leichman L, Groshen S, O'Neil BH, et al. Phase II study of olaparib (AZD-2281) after standard systemic therapies for disseminated colorectal cancer. Oncologist. 2016;21:172–177.
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–1708.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Im SA, Lee KW, et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol. 2015;33:3858–3865.
   PubMed Web of Science ®Google Scholar
• Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010;116:4578–4587.
   PubMed Web of Science ®Google Scholar
• Schaefer NG, James E, Wahl RL. Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma. Nucl Med Commun. 2011;32:1046–1051.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Li Y, Murray D, et al. 5-Aza-2′-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010;34:364–372.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Zander AR, Song G, et al. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer J. 2014;4:e171.
   PubMed Web of Science ®Google Scholar
• Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene. 2008;27:6522–6537.
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858–5868.
   PubMed Web of Science ®Google Scholar
• Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1:179–186.
   PubMed Web of Science ®Google Scholar
• Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014;12:94.
   PubMed Web of Science ®Google Scholar
• Wei L, Nakajima S, Hsieh CL, et al. Damage response of XRCC1 at sites of DNA single strand breaks is regulated by phosphorylation and ubiquitylation after degradation of poly(ADP-ribose). J Cell Sci. 2013;126:4414–4423.
   PubMed Web of Science ®Google Scholar
• D'Amours D, Jackson SP. The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat Rev Mol Cell Biol. 2002;3:317–327.
   PubMed Web of Science ®Google Scholar
• Zhao S, Weng YC, Yuan SS, et al. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature. 2000;405:473–477.
   PubMed Web of Science ®Google Scholar
• Vidal AE, Boiteux S, Hickson ID, et al. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein–protein interactions. EMBO J. 2001;20:6530–6539.
   PubMed Web of Science ®Google Scholar
• Whitehouse CJ, Taylor RM, Thistlethwaite A, et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 2001;104:107–117.
   PubMed Web of Science ®Google Scholar
• Caldecott KW, McKeown CK, Tucker JD, et al. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol. 1994;14:68–76.
   PubMed Web of Science ®Google Scholar
• Masson M, Niedergang C, Schreiber V, et al. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 1998;18:3563–3571.
   PubMed Web of Science ®Google Scholar
• Hartlerode AJ, Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J. 2009;423:157–168.
   PubMed Web of Science ®Google Scholar
• Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–489.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Shi Y, Tian C, et al. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene. 2004;23:1239–1247.
   PubMed Web of Science ®Google Scholar
• Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397:441–446.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Wang G, Murray D, et al. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013;41:719–730.
   PubMed Web of Science ®Google Scholar
• Suski JM, Lebiedzinska M, Bonora M, et al. Relation between mitochondrial membrane potential and ROS formation. Methods Mol Biol. 2012;810:183–205.
   PubMedGoogle Scholar
• Aoki H, Kang PM, Hampe J, et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem. 2002;277:10244–10250.
   PubMed Web of Science ®Google Scholar
• Ichijo H. From receptors to stress-activated MAP kinases. Oncogene. 1999;18:6087–6093.
   PubMed Web of Science ®Google Scholar
• Lau E, Ronai ZA. ATF2 – at the crossroad of nuclear and cytosolic functions. J Cell Sci. 2012;125:2815–2824.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Thall P, Valdez B, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012;18:1677–1686.
   PubMed Web of Science ®Google Scholar
• Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 1991;51:2386–2394.
   PubMed Web of Science ®Google Scholar
• D'Amours D, Desnoyers S, D'Silva I, et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999;342:249–268.
   PubMed Web of Science ®Google Scholar
• Zaja R, Mikoč A, Barkauskaite E, et al. Molecular insights into poly(ADP-ribose) recognition and processing. Biomolecules. 2012;3:1–17.
   PubMedGoogle Scholar
• Hayakawa J, Depatie C, Ohmichi M, et al. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem. 2003;278:20582–20592.
   PubMed Web of Science ®Google Scholar
• Bhoumik A, Lopez-Bergami P, Ronai Z. ATF2 on the double-activating transcription factor and DNA damage response protein. Pigment Cell Res. 2007;20:498–506.
   PubMedGoogle Scholar
• Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs. 2012;30:1493–1500.
   PubMed Web of Science ®Google Scholar
• Khan OA, Gore M, Lorigan P, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer. 2011;104:750–755.
   PubMed Web of Science ®Google Scholar
• Del Conte G, Sessa C, von Moos R, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer. 2014;111:651–659.
   PubMed Web of Science ®Google Scholar
• Palma JP, Wang YC, Rodriguez LE, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009;15:7277–7290.
   PubMed Web of Science ®Google Scholar
• Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011;71:5626–5634.
   PubMed Web of Science ®Google Scholar
• Golla RM, Li M, Shen Y, et al. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks. Hematol Oncol. 2012;30:175–179.
   PubMed Web of Science ®Google Scholar